Prostanoids for pulmonary arterial hypertension.

Area of Science:

• Cardiology
• Pulmonology
• Pharmacology

Background:

• Pulmonary arterial hypertension (PAH) is a severe condition characterized by increased pulmonary vascular resistance, leading to right ventricular failure.
• Dysregulation of prostacyclin pathways is implicated in PAH pathophysiology, justifying exogenous prostacyclin administration.
• Prostacyclin analogs offer vasodilatory, antiplatelet, and antiproliferative effects, crucial for managing PAH.

Purpose of the Study:

• To review the therapeutic use of prostacyclin analogs in pulmonary arterial hypertension (PAH).
• To compare the efficacy and tolerability of different prostacyclin analogs and administration routes in PAH patients.

Main Methods:

• Review of clinical trials evaluating prostacyclin analogs (epoprostenol, treprostinil, beraprost sodium, iloprost) in PAH.
• Analysis of data on patient symptoms, exercise capacity, hemodynamics, survival, and adverse events.

Main Results:

• Epoprostenol improved symptoms, exercise capacity, and survival in NYHA class III/IV PAH patients.
• Subcutaneous treprostinil showed benefits in exercise and clinical events, with infusion site reactions noted.
• Oral beraprost sodium improved exercise capacity in PPH patients, and inhaled iloprost benefited PAH and chronic thromboembolic pulmonary hypertension patients.

Conclusions:

• Prostacyclin analogs demonstrate favorable effects in PAH patients across various administration routes.
• The distinct profiles of prostacyclin analogs allow for individualized treatment selection in PAH management.
• Further research may optimize the use of these agents for improved patient outcomes.